Plain-language · Issue 1 · 2026-09-24
Inhaled Antibiotics in CF: Registry Evidence Suggests Diminishing Returns and Emerging Risks in the Modulator Era
Editorially reviewed research summaries, context, and limitations.
Marianne S Muhlebach, Jane She, John J LiPuma, et al.
Summary: This study used data from the US CF Foundation Patient Registry, covering roughly 12,000 to 16,000 people with CF each year from 2011 to 2019, to ask whether inhaled antibiotic therapy — long a standard part of CF treatment — is still providing the same benefits now that CFTR modulator medicines have changed the disease landscape. The researchers found that the lung-function benefit of inhaled antibiotics appeared mainly in patients who had a chronic infection with a bacterium called Pseudomonas aeruginosa. In patients without that infection, inhaled antibiotics showed no benefit — and in some cases were linked to worse lung function. Use of inhaled antibiotics was also associated with higher rates of infection from other difficult-to-treat organisms, including a fungus called Aspergillus. Across the years studied, the lung-function benefit of antibiotics appeared to weaken as CFTR modulator use grew.
Why it matters: Inhaled antibiotics have been part of CF care for decades, and many patients take them routinely. But the arrival of CFTR modulators — drugs that treat the underlying cause of CF rather than just the symptoms — has changed what CF looks like for many patients. Fewer patients now develop the chronic Pseudomonas infections that antibiotics were mainly designed to fight. This study raises a practical question: are some patients continuing to take inhaled antibiotics out of established habit when the benefit may no longer outweigh the risk of encouraging other infections? The findings suggest that prescribing decisions may need to be revisited, particularly for patients who do not have chronic Pseudomonas infection.
What to keep in mind: This is an observational study — researchers tracked what happened to patients over time rather than randomly assigning treatments. That means sicker patients were more likely to be prescribed inhaled antibiotics, and differences in how sick patients were at the start may partly explain some of the results, even though the researchers used statistical methods to try to account for this. It is also not possible from this data alone to confirm that the antibiotics caused the infections with other organisms, though there are plausible biological reasons to think they might. Importantly, the data only go up to 2019, before the most powerful current modulator — ETI — was in widespread use. The picture today may look quite different, and the case for re-examining antibiotic prescribing may actually be stronger now. This study builds a credible case for reconsidering standard practices, but it would need to be followed up with studies using more recent data before guidelines change.
Relevance: Cystic Fibrosis | CF Registry and Real-World Evidence
Source: https://pubmed.ncbi.nlm.nih.gov/42767597/
---